Search

Displaying results 2921 - 2930 of 10000 in total
  1. Drug

    Malathion

    go.drugbank.com/drugs/DB00772
    Approved

    Malathion is a parasympathomimetic organophosphate compound that is used as an insecticide for the treatment of head lice. … Malathion is an irreversible cholinesterase inhibitor and has low human toxicity.

    Categories: Compounds used in a research, industrial, or household settingProducts: A-FLEAZ SHAMPOO 1% w/w
  2. Drug

    Nemolizumab

    go.drugbank.com/drugs/DB15252
    ApprovedInvestigational

    Nemolizumab is a humanized monoclonal modified immunoglobulin 2 (IgG2) antibody directed against interleukin-31 receptor alpha (IL-31RA),[L51159] which is an endogenous cytokine implicated in the pathophysiology … [L51159] Nemolizumab gained its first global approval in Japan on March 28, 2022, for the treatment of atopic dermatitis.

    Synonyms: Immunoglobulin G2, anti-(interleukin 31 receptor A) (human-Mus musculus monoclonal CIM331 γ-chain), disulfide with human-Mus musculus monoclonal CIM331 κ-chain, dimer
  3. Drug

    Anileridine

    go.drugbank.com/drugs/DB00913
    ApprovedIllicitWithdrawn

    Anileridine is a synthetic opioid and strong analgesic medication. It is a narcotic pain reliever used to treat moderate to severe pain. … Narcotic analgesics act in the central nervous system (CNS) to relieve pain. Some of their side effects are also caused by actions in the CNS.

    Synonyms: N-β-(p-aminophenyl)ethylnormeperidine, N-(β-(p-aminophenyl)ethyl)-4-phenyl-4-carbethoxypiperidine
  4. Drug

    Lifileucel

    go.drugbank.com/drugs/DB17107
    ApprovedInvestigational

    Lifileucel is a tumour-derived autologous T cell immunotherapy composed of a suspension of tumour-derived T cells from the patient [L50171] which undergo isolation, ex vivo expansion, and activation[A263341 … ] Lifileucel was granted accelerated approval by the FDA on February 16, 2024, for the treatment of unresectable or metastatic melanoma.

  5. Drug

    Ixazomib

    go.drugbank.com/drugs/DB09570
    ApprovedInvestigational

    Ixazomib is a reversible proteasome inhibitor. Because it is a modified peptide boronic acid with one chiral center,[A264329] it is considered a boronate proteasome inhibitor. … [L51244] It was also investigated in other hematological malignancies as well as other conditions, such as systemic light chain (AL) amyloidosis, graft-versus-host disease, and lupus nephritis.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index
  6. Drug

    Racemethionine

    go.drugbank.com/drugs/DB13972
    Approved

    A preparation of methionine that includes a mixture of D-methionine and L-methionine isomers.

    Mixtures: AMINOPLASMAL® 10% E, Extra Once A Day
  7. Drug

    Sodium phosphate, dibasic, unspecified form

    go.drugbank.com/drugs/DB14504
    Approved

    Mixtures: gent-L-tip, Aminosyn II in Dextrose
  8. Drug

    Streptozocin

    go.drugbank.com/drugs/DB00428
    ApprovedInvestigational

    An antibiotic that is produced by Stretomyces achromogenes. It is used as an antineoplastic agent and to induce diabetes in experimental animals.

    Synonyms: N-D-Glucosyl-(2)-N'-nitrosomethylurea, N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff
  9. Drug

    Telisotuzumab vedotin

    go.drugbank.com/drugs/DB15104
    ApprovedInvestigational

    Telisotuzumab vedotin is an antibody-drug conjugate comprising [telisotuzumab], a c-Met-directed humanized IgG1κ monoclonal antibody, conjugated to monomethyl auristatin E (MMAE), a small molecule microtubule-disrupting … agent, via a protease-cleavable valine-citrulline linker.

  10. Drug

    Daraxonrasib

    go.drugbank.com/drugs/DB22308
    ApprovedInvestigational

    [L64039] It is a RAS(ON) tri-complex inhibitor that binds cyclophilin A and targets the active, GTP-bound ("ON") state of RAS, suppressing signaling of both wild-type and mutant RAS across the most common … [L64039,L64041] Because it targets a broad range of RAS genotypes, it treats tumors with or without an identified RAS mutation and does not require a companion diagnostic test.